 |
 |
| |
| |
| |
| |
In today’s biopharmaceutical and medical device R&D environment the focus is on product acquisition. It is a strategic device to combat stiff competition from generics, poor R&D productivity, shallow pipelines, gain market penetration in new geographies, fill out or specialize product and technology offerings and increase a company’s customer base. No matter whether the transaction is a merger, partnership, licensing agreement, outsourcing arrangement or capital investment, the risks of a poorly managed process and imprudent decisions are high and can be quite costly both at the point of transaction and afterwards. Making the right decision is often essential to commercial success.
Alternatively, companies who seek investment capital or want to sell a product or their company as a whole, require due diligence to help ensure their attractiveness to the market and fair valuation of their assets.
At PAREXEL Consulting our goal is to use our scientific, regulatory, and business expertise to perform thorough due diligence essential to help optimize the value of strategic business transactions. Our experts help facilitate independent informed assessments and decision-making, and position companies and their products to their best advantage. After all, our mission is to help drive our client’s product and business performance no matter what side of a transaction you’re on. Contact us today to discuss how we can help optimize your business strategies.
US: Vice President, Ron Kraus
Cell: 978-848-2634
E-mail: ron.kraus@parexel.com
International: Vice President, Paul Bridges
Cell: +44 (0) 1895 614956
E-mail: paul.bridges@parexel.com